1. |
葛均波, 徐永健. 内科学. 第8版. 北京:人民卫生出版社, 2013:733-756.
|
2. |
Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in china. N Engl J Med, 2010, 362(12):1090-1101.
|
3. |
Higgins Jpt, Green S. Cochrane handbook for systematic re views of interventions version 5.1.0[updated march 2011]. The cochrane collaboration, 2011. Available at:www.cochrane-handbook.org.2012-11-27/2012-12-10.
|
4. |
Bajaj M, Gilman R, Patel S, et al. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone:a 24-week randomized, double-blind study. Diabet Med, 2014, 31(12):1505-1514.
|
5. |
Barnett AH, Patel S, Harper R, et al. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate:an 18-week randomized, double-blind, placebo-controlled phase iii trial with a 34-week active-controlled extension. Diabetes Obes Metab, 2012, 14(12):1145-1154.
|
6. |
Barnett AH, Huisman H, Jones R, et al. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments:a randomised, double-blind, placebo-controlled trial. Lancet, 2013, 382(9902):1413-1423.
|
7. |
Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes:a randomized controlled trial.Diabetes Obes Metab, 2011, 13(3):258-267.
|
8. |
Forst T, Uhlig-Laske B, Ring A, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabet Med, 2010, 27(12):1409-1419.
|
9. |
Gomis R, Espadero RM, Jones R, et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes:a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab, 2011, 13(7):653-661.
|
10. |
Haak T, Meinicke T, Jones R, et al. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes:a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab, 2012, 14(6):565-574.
|
11. |
Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in japanese patients with type 2 diabetes:a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab, 2012, 14(4):348-357.
|
12. |
Lajara R, Aguilar R, Hehnke U, et al. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (> 10 years):evidence from pooled data of randomized, double-blind, placebo-controlled, phase Ⅲ trials. Clin Ther, 2014, 36(11):1595-1605.
|
13. |
Lewin AJ, Arvay L, Liu D, et al. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus:an 18-week, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther, 2012, 34(9):1909-1919.
|
14. |
Owens DR, Swallow R, Dugi KA, et al. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea:a 24-week randomized study. Clin Ther, 2011, 28(11):1352-1361.
|
15. |
Ross SA, Rafeiro E, Meinicke T, et al. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin:a randomised, double-blind, placebo-controlled trial. Curr Med Res Opin, 2012, 28(9):1465-1474.
|
16. |
Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes:a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab, 2011, 13(1):65-74.
|
17. |
Thrasher J, Daniels K, Patel S, et al. Efficacy and safety of linagliptin in black/african american patients with type 2 diabetes:a 6-month, randomized, double-blind, placebo-controlled study. Endocr Pract, 2014, 20(5):412-420.
|
18. |
Wang W, Yang J, Yang G, et al. Efficacy and safety of linagliptin in asian patients with type 2 diabetes mellitus inadequately controlled by metformin:a multinational 24-week, randomized clinical trial. J Diabetes, 2015, doi:10.1111/1753-0407.
|
19. |
Zeng Z, Yang JK, Tong N, et al. Efficacy and safety of linagliptin added to metformin and sulphonylurea in chinese patients with type 2 diabetes:a sub-analysis of data from a randomised clinical trial. Curr Med Res Opin, 2013, 29(8):921-929.
|
20. |
Aletti R, Cheng LA. Linagliptin:the newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus. Cardiol Rev, 2012, 20(1):45-51.
|
21. |
Blech S, Ludwig SE, Graefe ME, et al. The metabolism and disposition of the dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos, 2010, 38(4):667-678.
|
22. |
Graefe MU, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab, 2011, 13(10):939-946.
|
23. |
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med, 2013, 369(14):1317-1326.
|